HC Wainwright & Co. Initiates Coverage On AEON Biopharma with Buy Rating, Announces Price Target of $18
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Douglas Tsao has initiated coverage on AEON Biopharma (AMEX:AEON) with a Buy rating and a price target of $18.
August 18, 2023 | 10:18 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AEON Biopharma has been given a Buy rating by HC Wainwright & Co. with a price target of $18.
The Buy rating and price target of $18 announced by HC Wainwright & Co. for AEON Biopharma indicates a positive outlook for the company's stock. This could potentially attract investors, driving up the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100